JFL Life Sciences Limited

JFLLIFE

INE0LA901015

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:53 2024-06-27 am EDT			5-day change	1st Jan Change
40.8 ^INR	0.00%		-0.85%	-1.69%

2023	JFL Life Sciences Limited Reports Earnings Results for the Half Year Ended September 30, 2023	CI
2023	Certain Equity Shares of JFL Life Sciences Limited are subject to a Lock-Up Agreement Ending on 5-SEP-2023.	CI

JFL Life Sciences Limited has withdrawn its IPO.

May 30, 2022 at 12:00 am EDT

JFL Life Sciences Limited has withdrawn its IPO.

Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 3,000,000

Transaction Features: Regulation S

Latest news about JFL Life Sciences Limited

JFL Life Sciences Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 08	CI
Certain Equity Shares of JFL Life Sciences Limited are subject to a Lock-Up Agreement Ending on 5-SEP-2023.	23-09-04	CI
JFL Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-27	CI
JFL Life Sciences Limited Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-12	CI
JFL Life Sciences Limited has completed an IPO in the amount of INR 181.658 million.	22-09-08	CI
JFL Life Sciences Limited has filed an IPO.	22-05-31	CI
JFL Life Sciences Limited has withdrawn its IPO.	22-05-30	CI
JFL Life Sciences Limited has filed an IPO.	22-04-12	CI

Chart JFL Life Sciences Limited

Duration

Period

More charts

JFL Life Sciences Limited is an India-based pharmaceutical company. The Company's business segment comprises the manufacturing and selling of pharmaceutical products. The Company is engaged in producing and marketing a wide range of formulations. The Company has manufacturing facilities with trading and related activities extending to the global market. Its manufacturing facilities are located at Kerala, Bavla, Ahmedabad, Gujarat. The Company's main product categories include dry powder injections, tablets and capsules (B-Lactam) solid oral dosage form, tablet and capsules (general), and ORS. Its beta lactam dry powder injection products include Ampicillin Injection, Cefotaxime Sodium Injection -250 Mg, Cefazoline Sodium Injection and meropenem injection - 1 gm. Its beta lactam tablet and capsule products include Cefadroxil Tablets 500 mg and Cefadroxil Capsules 500 mg. Its general tablet and capsule products include Azithromycin Tablets - 500 mg and Ofloxacin Tablets - 200 mg.

Sector

Pharmaceuticals

Calendar

2024-11-07 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JFL LIFE SCIENCES LIMITED	-1.69%	5.37M
ELI LILLY AND COMPANY	+55.33%	811B
NOVO NORDISK A/S	+43.73%	640B
JOHNSON & JOHNSON	-6.29%	353B
MERCK & CO., INC.	+19.44%	333B
ABBVIE INC.	+9.66%	302B
ASTRAZENECA PLC	+17.06%	246B
ROCHE HOLDING AG	+2.58%	225B
NOVARTIS AG	+12.85%	218B
AMGEN INC.	+9.18%	168B